Keytruda Archives -

Keytruda fluffs its lines in prostate, liver cancer trials

Phil Taylor immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer 0 Comment

Two phase 3 trials of Merck & Co’s Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver

Keytruda fluffs its lines in prostate, liver cancer trials

https://pharmaphorum.com/news/keytruda-fluffs-its-lines-in-prostate-liver-cancer-trials/

Oncology/ Views & Analysis/ Views and analysis

Oncology market dominance: As easy as ADC?

Ben Hargreaves antibody-drug conjugates, Keytruda, Pfizer, Roche 0 Comment

Antibody-drug conjugates are coming back to the fore, with talks of multi-billion dollar buyouts and a rapidly growing

Oncology market dominance: As easy as ADC?

https://pharmaphorum.com/oncology/oncology-market-dominance-as-easy-as-adc/

News/ News/ News/ Oncology/ Sales and Marketing

Merck sees big lift in Keytruda sales, as Senate probes its taxes

Phil Taylor Financial, Gardasil, Keytruda, Lagevrio, Merck & Co, tax, US 0 Comment

Merck & Co has reported record sales of its cancer immunotherapy Keytruda in the second quarter, as members

Merck sees big lift in Keytruda sales, as Senate probes its taxes

https://pharmaphorum.com/news/merck-sees-big-lift-in-keytruda-sales-as-senate-probes-its-taxes/

News/ News/ News/ Oncology/ R&D

Bid to expand Keytruda use in head and neck cancer therapy fails

Phil Taylor head and neck cancer, immuno-oncology, Keytruda, Merck & Co, Oncology 0 Comment

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact

Bid to expand Keytruda use in head and neck cancer therapy fails

https://pharmaphorum.com/news/bid-to-expand-keytruda-use-in-head-and-neck-cancer-therapy-fails/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ News/ Oncology/ R&D

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo 0 Comment

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/

News/ News/ Oncology

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

Phil Taylor adjuvant, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

While Merck & Co’s Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there’s

Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC

https://pharmaphorum.com/news/roches-tecentriq-extends-lead-over-keytruda-in-adjuvant-nsclc/

News/ News/ Oncology

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

Phil Taylor Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo, regulatory approval 0 Comment

The FDA has cleared two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously-untreated advanced

BMS’ Opdivo gets late-stage oesophageal cancer nod from FDA

https://pharmaphorum.com/news/bms-opdivo-gets-late-stage-oesophageal-cancer-nod-from-fda/

Market Access/ News/ News/ News/ Oncology

NICE finds solution to making Keytruda available for TNBC

Phil Taylor HEOR, Keytruda, market access, Merck & Co, NICE, Roche, Tecentriq, triple negative breast cancer 0 Comment

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other

NICE finds solution to making Keytruda available for TNBC

https://pharmaphorum.com/news/nice-finds-solution-to-making-keytruda-available-for-tnbc/

Trending

Keytruda

Login